Armata Pharmaceuticals (ARMP) AI Stock Analysis

• Market Cap: $233.37M
• Dividend Yield: N/A
• Average Volume (3M): 536.86K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.79
• Revenue Growth: -7.55%
• EPS Growth: -13.09%
• Country: US
• Employees: 60
• Sector: N/A
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -0.74
• Shares Outstanding: 36,406,906
• 10 Day Avg. Volume: 121,090
• 30 Day Avg. Volume: 536,864
• PEG Ratio: 0.05
• Price to Book (P/B): -1.39
• Price to Sales (P/S): 12.93
• P/FCF Ratio: -1.70
• Enterprise Value/Market Cap: 1.16
• Enterprise Value/Revenue: 53.60
• Enterprise Value/Gross Profit: 76.07
• Enterprise Value/Ebitda: -8.92
• 1Y Price Target: $9.00
• Price Target Upside: 158.62% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: $5.50 ▲(58.05% Upside)

Armata Pharmaceuticals' overall stock score is primarily impacted by its poor financial performance, which is a significant risk. However, positive corporate events, including promising clinical trial results and strategic advancements in phage therapy, provide potential upside. Technical analysis and valuation present mixed signals, with some medium-term technical strength but unattractive valuation metrics.

Armata Pharmaceuticals Business Overview & Revenue Model

Company Description

Armata Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for the treatment of bacterial infections. The company specializes in harnessing the power of bacteriophage technology, which utilizes viruses that specifically target and kill bacteria. Armata's core product offerings include its proprietary phage therapies designed to address antibiotic-resistant infections, with an emphasis on personalized medicine approaches to combat specific pathogens.

How the Company Makes Money

Armata Pharmaceuticals generates revenue primarily through the development and commercialization of its bacteriophage therapies. This includes revenue from potential licensing agreements, partnerships with pharmaceutical companies, and government grants aimed at advancing antibiotic alternatives. The company may also benefit from milestone payments tied to successful clinical development phases and regulatory approvals of its therapies. Additionally, collaboration with research institutions and healthcare providers can create pathways for further funding and resource allocation, enhancing its financial stability.

Armata Pharmaceuticals Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Armata Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.48
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARMP, the sentiment is Positive. The current price of 3.48 is below the 20-day moving average (MA) of 6.07, below the 50-day MA of 5.87, and above the 200-day MA of 3.08, indicating a bullish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 54.79 is Neutral, neither overbought nor oversold. The STOCH value of 87.64 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ARMP.

Armata Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	―	―	―	―	―	―
ADAG	52 Neutral	$87.19M	-2.76	-63.41%	―	-87.59%	11.53%
ARMP	50 Neutral	$233.37M	-4.97	―	―	-7.55%	-13.09%
ORMP	47 Neutral	$125.38M	2.94	24.38%	―	―	814.20%
VERU	45 Neutral	$37.56M	-1.88	-61.92%	―	-100.00%	55.10%
ELUT	41 Neutral	$23.88M	-0.59	―	―	-14.92%	72.81%
INKT	38 Underperform	$55.86M	-3.94	―	―	―	21.48%

Armata Pharmaceuticals Corporate Events

Armata Pharmaceuticals Enters Capital Sales Agreement

On December 1, 2025, Armata Pharmaceuticals entered into a Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC. This agreement allows Armata to offer and sell up to $100 million in common stock through an at-the-market offering program. The sales will be conducted by Jones as the sales agent, with Armata paying a commission of up to 3% on gross sales proceeds. This strategic move aims to bolster Armata’s financial flexibility and enhance its market presence, potentially impacting its operations and stakeholder interests.

Armata Pharmaceuticals Reports Positive Phase 2a Study Results

On October 22, 2025, Armata Pharmaceuticals announced positive results from its Phase 2a diSArm study of AP-SA02, a bacteriophage cocktail for treating complicated Staphylococcus aureus bacteremia, presented at IDWeek 2025. The study demonstrated higher cure rates and no relapse in patients treated with AP-SA02 compared to placebo, supporting the advancement to a Phase 3 trial. These findings suggest AP-SA02 could become a new standard of care for this severe infection, with implications for reducing hospital stays and improving patient outcomes.

Armata Pharmaceuticals Highlights Phage Therapy Progress

On September 10, 2025, Armata Pharmaceuticals‘ CEO, Dr. Deborah Birx, presented at the H.C. Wainwright 27th Annual Global Investment Conference. The presentation highlighted the company’s progress and strategic plans in developing phage-based therapies, emphasizing their potential to address the global threat of antibiotic resistance. Armata is focused on conducting definitive pivotal trials to establish the efficacy and safety of phage therapy as an alternative or complement to standard antibiotics, aiming to position itself as a leader in this innovative field.